The “Wild West” Cosmetic Sector. Again.

This week the Women and Equalities Committee described the UK cosmetic sector as a “wild west”.

If you’ve been in this industry a while, you probably didn’t gasp.

You probably thought, well… yes.

But here’s what’s uncomfortable.

We were told this before.

In 2013, Professor Sir Bruce Keogh reviewed cosmetic interventions after the PIP scandal. He highlighted poor training standards, weak oversight, fragmented complaints systems and the growing commercialisation of procedures without proper medical governance.

That was twelve years ago.

Twelve years of explosive growth in injectables. Twelve years of Social Media marketing. Twelve years of increasingly complex procedures being normalised.

And structurally? We are still largely relying on voluntary systems.

The Women and Equalities Committee has now said what Keogh said then: the gap remains. High risk procedures are being performed by people without adequate training. There is still no mandatory qualification framework for many non surgical treatments. Enforcement is inconsistent. The public can’t easily tell who is operating safely and who is not.

The JCCP (Joint Council for Cosmetic Practitioners) welcomed the report and called, again, for meaningful regulation.

So why are we still here?

I personally think part of the issue is that aesthetics lives in an awkward space. It is healthcare, but it’s also commerce. It is elective, but it’s invasive. That makes it politically very easy to push down the priority list.

There’s also a discomfort about being seen to over regulate. Cosmetic procedures are framed as consumer choice. Governments are cautious about appearing paternalistic.

But here’s the reality. When something goes wrong, it does not land in a beauty complaints inbox. It lands in A & E.

And then it becomes healthcare.

Another issue is that harm is dispersed. Complications aren’t collected in one national database. They show up in emergency departments, GP surgeries and private follow up clinics. Without mandatory reporting, the scale feels abstract. And when something feels abstract, it is easier to delay action.

Meanwhile, responsible practitioners are already working to medical standards. We document properly. We prescribe within governance frameworks. We carry indemnity. We manage complications. We decline inappropriate treatment.

But none of that’s mandatory across the board.

That’s the problem.

This isn’t about being anti-aesthetics. It is about being honest. These are invasive procedures involving anatomy, pharmacology and risk. The regulatory framework should reflect that.

What (in my opinion) should happen?

A tiered, risk based licensing system. High risk injectables within regulated healthcare. Accredited training standards for everyone else. Mandatory complication reporting. Clear advertising enforcement. Transparency around qualifications.

Nothing radical. Just basic patient safety infrastructure.

Keogh warned us in 2013.

The Women and Equalities Committee has warned us in 2026.

At some point, repeating the warning without implementing the solution starts to look less like complexity and more like reluctance, especially when people are losing their lives.

The sector has evolved.

Regulation now needs to catch up.

This matters because without clear regulation, patients cannot easily distinguish between medically trained practitioners and unqualified providers. Stronger standards mean safer treatment, better accountability and greater protection if something goes wrong.